Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39
Loading...
Contact
Check for full-text access
Issue Date
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: In the phase III EV-302 study, EV+P demonstrated statistically significantly prolonged overall survival (OS) and progression-free survival (PFS) vs chemo in patients (pts) with previously untreated la/mUC. Here, we present a post hoc pan-Asian subgroup analysis of EV-302.
Description
Citation
Publisher
License
Journal
Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO
Volume
Issue
06-Aug